Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent

Mohamed Wehbe,1,2 Malathi Anantha,1 Minghan Shi,3,4 Ada Wai-yin Leung,1 Wieslawa H Dragowska,1 Léon Sanche,3,4 Marcel B Bally1,2,5,6 1Experimental Therapeutics, British Columbia Cancer Agency, 2Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, 3Department...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wehbe M, Anantha M, Shi M, Leung AWY, Dragowska WH, Sanche L, Bally MB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	disulfiram copper diethyldithiocarbamate cancer copper complexes liposomes. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/afc7a2fd99a646aa995a9ad0fa9c690e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:afc7a2fd99a646aa995a9ad0fa9c690e
record_format	dspace
spelling	oai:doaj.org-article:afc7a2fd99a646aa995a9ad0fa9c690e2021-12-02T08:07:46ZDevelopment and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent1178-2013https://doaj.org/article/afc7a2fd99a646aa995a9ad0fa9c690e2017-05-01T00:00:00Zhttps://www.dovepress.com/development-and-optimization-of-an-injectable-formulation-of-copper-di-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Mohamed Wehbe,1,2 Malathi Anantha,1 Minghan Shi,3,4 Ada Wai-yin Leung,1 Wieslawa H Dragowska,1 Léon Sanche,3,4 Marcel B Bally1,2,5,6 1Experimental Therapeutics, British Columbia Cancer Agency, 2Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, 3Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Science, 4Faculté de médecine et des sciences de la santé, Center for Research in Radiotherapy, Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Québec, QC, 5Department of Pathology and Laboratory Medicine, University of British Columbia, 6Faculty of Medicine, Center for Drug Research and Development, Vancouver, BC, Canada Abstract: Copper diethyldithiocarbamate (Cu(DDC)2) is the active anticancer agent generated when disulfiram (DSF) is provided in the presence of copper. To date, research directed toward repurposing DSF as an anticancer drug has focused on administration of DSF and copper in combination, efforts that have proven unsuccessful in clinical trials. This is likely due to the inability to form Cu(DDC)2 at relevant concentrations in regions of tumor growth. Little effort has been directed toward the development of Cu(DDC)2 because of the inherent aqueous insolubility of the complex. Here, we describe an injectable Cu(DDC)2 formulation prepared through a method that involves synthesis of Cu(DDC)2 inside the aqueous core of liposomes. Convection-enhanced delivery of a Cu(DDC)2 formulation prepared using 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)/cholesterol liposomes into a rat model of F98 glioma engendered a 25% increase in median survival time relative to vehicle-treated animals. In a murine subcutaneous MV-4–11 model, treatment resulted in a 45% reduction in tumor burden when compared to controls. Pharmacokinetic studies indicated that the Cu(DDC)2 was rapidly eliminated after intravenous administration while the liposomes remained in circulation. To test whether liposomal lipid composition could increase Cu(DDC)2 circulation lifetime, a number of different formulations were evaluated. Studies demonstrated that liposomes composed of DSPC and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-n-(carboxy[polyethylene glycol]-2000) (95:5) enhanced Cu(DDC)2 concentrations in the circulation as reflected by a 4.2-fold increase in plasma AUC(0-∞) relative to the DSPC/cholesterol formulation. The anticancer activity of this Cu(DDC)2 formulation was subsequently evaluated in the MV-4–11 model. At its maximum tolerated dose, this formulation exhibited comparable activity to the DSPC/cholesterol formulation. This is the first report demonstrating the therapeutic effects of an injectable Cu(DDC)2 formulation in vivo. Keywords: disulfiram, copper diethyldithiocarbamate, cancer, copper complexes, liposomesWehbe MAnantha MShi MLeung AWYDragowska WHSanche LBally MBDove Medical Pressarticledisulfiramcopper diethyldithiocarbamatecancercopper complexesliposomes.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 4129-4146 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	disulfiram copper diethyldithiocarbamate cancer copper complexes liposomes. Medicine (General) R5-920
spellingShingle	disulfiram copper diethyldithiocarbamate cancer copper complexes liposomes. Medicine (General) R5-920 Wehbe M Anantha M Shi M Leung AWY Dragowska WH Sanche L Bally MB Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent
description	Mohamed Wehbe,1,2 Malathi Anantha,1 Minghan Shi,3,4 Ada Wai-yin Leung,1 Wieslawa H Dragowska,1 Léon Sanche,3,4 Marcel B Bally1,2,5,6 1Experimental Therapeutics, British Columbia Cancer Agency, 2Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, 3Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Science, 4Faculté de médecine et des sciences de la santé, Center for Research in Radiotherapy, Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Québec, QC, 5Department of Pathology and Laboratory Medicine, University of British Columbia, 6Faculty of Medicine, Center for Drug Research and Development, Vancouver, BC, Canada Abstract: Copper diethyldithiocarbamate (Cu(DDC)2) is the active anticancer agent generated when disulfiram (DSF) is provided in the presence of copper. To date, research directed toward repurposing DSF as an anticancer drug has focused on administration of DSF and copper in combination, efforts that have proven unsuccessful in clinical trials. This is likely due to the inability to form Cu(DDC)2 at relevant concentrations in regions of tumor growth. Little effort has been directed toward the development of Cu(DDC)2 because of the inherent aqueous insolubility of the complex. Here, we describe an injectable Cu(DDC)2 formulation prepared through a method that involves synthesis of Cu(DDC)2 inside the aqueous core of liposomes. Convection-enhanced delivery of a Cu(DDC)2 formulation prepared using 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)/cholesterol liposomes into a rat model of F98 glioma engendered a 25% increase in median survival time relative to vehicle-treated animals. In a murine subcutaneous MV-4–11 model, treatment resulted in a 45% reduction in tumor burden when compared to controls. Pharmacokinetic studies indicated that the Cu(DDC)2 was rapidly eliminated after intravenous administration while the liposomes remained in circulation. To test whether liposomal lipid composition could increase Cu(DDC)2 circulation lifetime, a number of different formulations were evaluated. Studies demonstrated that liposomes composed of DSPC and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-n-(carboxy[polyethylene glycol]-2000) (95:5) enhanced Cu(DDC)2 concentrations in the circulation as reflected by a 4.2-fold increase in plasma AUC(0-∞) relative to the DSPC/cholesterol formulation. The anticancer activity of this Cu(DDC)2 formulation was subsequently evaluated in the MV-4–11 model. At its maximum tolerated dose, this formulation exhibited comparable activity to the DSPC/cholesterol formulation. This is the first report demonstrating the therapeutic effects of an injectable Cu(DDC)2 formulation in vivo. Keywords: disulfiram, copper diethyldithiocarbamate, cancer, copper complexes, liposomes
format	article
author	Wehbe M Anantha M Shi M Leung AWY Dragowska WH Sanche L Bally MB
author_facet	Wehbe M Anantha M Shi M Leung AWY Dragowska WH Sanche L Bally MB
author_sort	Wehbe M
title	Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent
title_short	Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent
title_full	Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent
title_fullStr	Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent
title_full_unstemmed	Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent
title_sort	development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/afc7a2fd99a646aa995a9ad0fa9c690e
work_keys_str_mv	AT wehbem developmentandoptimizationofaninjectableformulationofcopperdiethyldithiocarbamateanactiveanticanceragent AT anantham developmentandoptimizationofaninjectableformulationofcopperdiethyldithiocarbamateanactiveanticanceragent AT shim developmentandoptimizationofaninjectableformulationofcopperdiethyldithiocarbamateanactiveanticanceragent AT leungawy developmentandoptimizationofaninjectableformulationofcopperdiethyldithiocarbamateanactiveanticanceragent AT dragowskawh developmentandoptimizationofaninjectableformulationofcopperdiethyldithiocarbamateanactiveanticanceragent AT sanchel developmentandoptimizationofaninjectableformulationofcopperdiethyldithiocarbamateanactiveanticanceragent AT ballymb developmentandoptimizationofaninjectableformulationofcopperdiethyldithiocarbamateanactiveanticanceragent
_version_	1718398680058298368

Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent

Ejemplares similares